Data Readout

Perspective's VMT01 melanoma readout will test early signal of 2 of 7 responses

Perspective Therapeutics has already disclosed two confirmed responses among seven monotherapy patients in its MC1R-targeted radiopharmaceutical trial, ahead of a mid-to-late 2026 update.

By AppliedXLJuly 13, 2026Trial NCT05655312

Executive Summary

Perspective Therapeutics has already disclosed a response signal from its lead melanoma cohort, giving the upcoming update a concrete baseline to build on rather than a first look at the drug.
The trial is the only industry-sponsored program testing this receptor target in melanoma, so its maturing data carries outsized weight for how the mechanism is read across the field.
The next disclosure will show whether the early response signal holds as monotherapy and combination cohorts enroll further, and whether the safety profile stays clean as more patients accumulate follow-up.
The cohort behind the response signal is small, and the trial remains an early-phase, non-registrational study, so the update will inform development decisions rather than settle regulatory outcomes.

The catalyst

Perspective Therapeutics said in a January 12, 2026 update that it expects clinical updates on VMT01, its melanoma program, and PSV359, a separate program targeting FAP across tumors, in the second half of 2026. The melanoma update is tied to NCT05655312, a Phase 1/2a trial of VMT01 as monotherapy and in combination with nivolumab in adults with unresectable or metastatic melanoma who progressed on a prior systemic therapy. As of March 25, 2026, Perspective had already reported that its 3.0 mCi monotherapy cohort of seven patients produced two confirmed responses, a 29% response rate in that cohort, and that broader monotherapy safety data across 27 treated patients showed no dose-limiting toxicities, no Grade 4 or 5 treatment-related adverse events, and Grade 3 treatment-related adverse events in 30% of patients. Perspective+1

Probability of Success

Endpoint Met91%

Completes12%

Clinical Significance25%

Regulatory90%

What the trial tests

The registered primary endpoints cover the incidence and severity of adverse events and serious adverse events, objective response rate by RECIST v1.1, and the number of subjects with dose-limiting toxicities after the first dose of VMT01, given alone or with nivolumab. The trial is designed as a dose-finding and activity-screening study, not a registrational trial, and it enrolls patients with prior progression on systemic therapy who show MC1R-positive tumor uptake on screening imaging. The FDA granted Fast Track Designation to the VMT01 program for unresectable or metastatic melanoma with MC1R tumor expression in September 2024, a designation that reflects unmet need in this population rather than a signal on approval odds. NCT05655312

Enrollment and timing

The trial's target enrollment has grown from 52 to 264 patients in September 2024 and then to 300 patients in October 2025, an early-phase enrollment increase consistent with a trial expanding cohorts as dose levels and the nivolumab combination arm advance. The primary completion date moved from June 30, 2025 to December 31, 2027 over the same period, a 30-month extension that reflects the added combination cohort and expanded enrollment rather than a stalled program, since the trial has continued recruiting throughout. Both 3.0 mCi VMT01 monotherapy cohorts have since closed to enrollment as completed, with patient counts reported as of February 28, 2026, marking a normal cohort-closure step as the study moves toward its next dose level or the combination arm. NCT05655312+1

The competitive frame

No other industry-sponsored trial pairs the MC1R target with melanoma; the nearest peers targeting MC1R are Resomelagon Acetate and Melanotan II programs developed for vitiligo and other indications, and the nearest melanoma-indication trials in the broader field target PD-1, BRAF, or neoantigens rather than MC1R. That isolation means the trial's maturing dataset stands as the only direct human evidence for this specific receptor-targeted radiopharmaceutical approach in melanoma. Perspective's only completed prior VMT01-family trial in melanoma, a seven-patient imaging study (NCT04904120), is too small to establish a base rate for the drug class in this indication.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.